Back Bay Serves as Strategic and Financial Advisor to Codexis in Takeda Transaction

Codexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic Disorders

Codexis has announced a major licensing/partnering agreement with Takeda. Back Bay Life Science Advisors both initiated and was honored to serve as strategic and financial advisor to Codexis in the transaction with Takeda Pharmaceutical Company Limited.

This strategic collaboration will work to advance the research and development of novel gene therapies for specific disease indications, including the treatment of select lysosomal storage disorders and coagulation factor deficiencies.

For many years, Back Bay has been a partner to Codexis, advising across numerous strategic and development issues. True to the Back Bay model, this deal, which represents the culmination of our extensive strategic work together, was led by our investment banking team in full integration with our strategic advisors.
 
We are proud to remain champions of critical advances in healthcare and extend our warmest congratulations to Codexis, Takeda, and the many patients and caregivers who will benefit from this collaboration.

Read the Codexis announcement: Codexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic Disorders.